Trials / Conditions / Portopulmonary Hypertension

Portopulmonary Hypertension

8 registered clinical trials studyying Portopulmonary Hypertension — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Heart Problems in Children With Chronic Liver Disease NCT07502196	Assiut University	—
Not Yet Recruiting	Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension NCT07314814	Prof. Valérie Mc Lin	—
Withdrawn	Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension NCT03309592	Ochsner Health System	Phase 4
Completed	PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial NCT02382016	Actelion	Phase 4
Terminated	Revatio Portal-Pulmonary Arterial Hypertension Trial NCT01517854	University Health Network, Toronto	Phase 2
Withdrawn	Ambrisentan for Treatment of Portopulmonary Hypertension NCT01733095	Medical University of Graz	Phase 1 / Phase 2
Completed	A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With NCT01028651	United Therapeutics	—
Completed	Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial NCT01224210	Tufts Medical Center	Phase 3